Trial Profile
The efficacy of alogliptin and pioglitazone to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2015
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 11 Nov 2015 Status changed from not yet recruiting to discontinued, as reported by University Hospital Medical Information Network - Japan record.
- 24 Oct 2014 New trial record